.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Accenture
McKinsey
Daiichi Sankyo
Chubb
Cantor Fitzgerald
Argus Health
Deloitte
Chinese Patent Office
Johnson and Johnson
Colorcon

Generated: July 22, 2017

DrugPatentWatch Database Preview

GONAL-F RFF REDI-JECT Drug Profile

« Back to Dashboard

Which patents cover Gonal-f Rff Redi-ject, and when can generic versions of Gonal-f Rff Redi-ject launch?

Gonal-f Rff Redi-ject is a drug marketed by Emd Serono and is included in one NDA. There are two patents protecting this drug.

This drug has sixty patent family members in thirty-three countries.

The generic ingredient in GONAL-F RFF REDI-JECT is follitropin alfa/beta. There is one drug master file entry for this compound. Two suppliers are listed for this compound. Additional details are available on the follitropin alfa/beta profile page.

Summary for Tradename: GONAL-F RFF REDI-JECT

Patents:2
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Clinical Trials: see list56
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:GONAL-F RFF REDI-JECT at DailyMed

Pharmacology for Tradename: GONAL-F RFF REDI-JECT

Ingredient-typeGonadotropins
Drug ClassGonadotropin
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Emd Serono
GONAL-F RFF REDI-JECT
follitropin alfa/beta
INJECTABLE;SUBCUTANEOUS021684-001May 25, 2004RXYesYes7,741,268► SubscribeY ► Subscribe
Emd Serono
GONAL-F RFF REDI-JECT
follitropin alfa/beta
INJECTABLE;SUBCUTANEOUS021684-002May 25, 2004RXYesYes7,446,090► SubscribeY ► Subscribe
Emd Serono
GONAL-F RFF REDI-JECT
follitropin alfa/beta
INJECTABLE;SUBCUTANEOUS021684-001May 25, 2004RXYesYes7,446,090► SubscribeY ► Subscribe
Emd Serono
GONAL-F RFF REDI-JECT
follitropin alfa/beta
INJECTABLE;SUBCUTANEOUS021684-002May 25, 2004RXYesYes7,741,268► SubscribeY ► Subscribe
Emd Serono
GONAL-F RFF REDI-JECT
follitropin alfa/beta
INJECTABLE;SUBCUTANEOUS021684-003May 25, 2004RXYesYes7,741,268► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: GONAL-F RFF REDI-JECT

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Emd Serono
GONAL-F RFF REDI-JECT
follitropin alfa/beta
INJECTABLE;SUBCUTANEOUS021684-002May 25, 20045,767,067► Subscribe
Emd Serono
GONAL-F RFF REDI-JECT
follitropin alfa/beta
INJECTABLE;SUBCUTANEOUS021684-002May 25, 20045,767,251► Subscribe
Emd Serono
GONAL-F RFF REDI-JECT
follitropin alfa/beta
INJECTABLE;SUBCUTANEOUS021684-001May 25, 20045,767,067► Subscribe
Emd Serono
GONAL-F RFF REDI-JECT
follitropin alfa/beta
INJECTABLE;SUBCUTANEOUS021684-003May 25, 20045,767,251► Subscribe
Emd Serono
GONAL-F RFF REDI-JECT
follitropin alfa/beta
INJECTABLE;SUBCUTANEOUS021684-001May 25, 20045,767,251► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: GONAL-F RFF REDI-JECT

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,563,763FSH and FSH variant formulations, products and methods► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: GONAL-F RFF REDI-JECT

Country Document Number Estimated Expiration
Cyprus1111291► Subscribe
Canada2518903► Subscribe
South Korea20050110037► Subscribe
Taiwan200503750► Subscribe
Japan4719357► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: GONAL-F RFF REDI-JECT

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0024France► SubscribePRODUCT NAME: CORIFOLLITROPINE ALPHA; REGISTRATION NO/DATE: EU/1/09/609/001 20100125
00440Netherlands► SubscribePRODUCT NAME: CORIFOLLITROPIN ALFA; REGISTRATION NO/DATE: EU/1/09/609/001-002 20100125; FORMER OWNER: N.V. ORGANON, NL
C/GB10/022United Kingdom► SubscribePRODUCT NAME: CORIFOLLITROPIN ALFA; REGISTERED: UK EU/1/09/609/001 20100125; UK EU/1/09/609/002 20100125
C0010Belgium► SubscribePRODUCT NAME: FOLLITROPINE ALPHA; NAT. REGISTRATION NO/DATE: EU1/95/001/001 19951020; FIRST REGISTRATION: FI 11529 19940815
2010Austria► SubscribePRODUCT NAME: CORIFOLLITROPIN ALFA; REGISTRATION NO/DATE: EU/1/09/609/001-002 20100125
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Express Scripts
Farmers Insurance
Merck
UBS
Novartis
Mallinckrodt
US Army
Cipla
Federal Trade Commission
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot